In another signal of the deepening relationship between the pharma and AI sectors, Novartis chief executive Vas Narasimhan ...

Infectious disease experts from around the world are calling for concerted action to combat a "silent surge" in resistance to ...

Parkinson’s disease (PD) is entering a pivotal phase. For decades, treatment has centred on dopamine replacement to manage ...

Japanese pharma group Daiichi Sankyo has reached a deal to sell its consumer healthcare division to food and beverage giant ...

The Michael J Fox Foundation for Parkinson's Research (MJFF) has started working with Swiss biotech Biognosys on a project ...

For too long, MASLD care has relied on a narrow playbook: lifestyle advice, routine monitoring, and waiting for signs of ...

Amazon has pitched an AI-powered drug discovery platform to the biopharma industry that it says brings together computational ...

The FDA may have approved Eli Lilly's oral weight-loss drug Foundayo in record time, but it still needs to see more safety ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.

The UK is studying cases of pancreatitis in people taking drugs based on GLP-1 receptor agonists for weight loss or type 2 diabetes to see if a person's genetic profile may make them more vulnerable ...

On today’s episode of the pharmaphorum podcast, host Jonah Comstock speaks with Thomas Goetz, former executive editor of ...

For now, the FDA is simply asking trial sponsors to make sure they meet the required reporting standards, but it has also ...